[Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
Serial estimations of the hydroxyproline (OHP) excretion during chemotherapy were performed in 24 women bearing advanced breast carcinoma with skeletal metastases. There was a significant correlation between sensitivity of the metastases to treatment and OHP content of urine. Many factors, including age of patients, type, number and extent of metastases, don't influence OHP excretion. The estimation of the urinary OHP levels, with the changes after antiblastic treatment, can be useful in prognostic evaluation of the metastatic breast cancer.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis
D000970:Antineoplastic Agents; D006909:Hydroxyproline
Comportamento variabile dell'idrossiprolina urinaria nel cancro mammario con metastasi ossee.